In breast cancer (BC), KIF4A is a prominent oncogenic driver, exhibiting significant upregulation that correlates with tumour malignancy and poor prognosis, demonstrating predictive power that surpasses traditional clinical indicators [15, 29, 46]. Here, KIF4A is linked to neoplasm.